Clinical Trials Browser

Prostate Adenocarcinoma

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Advanced Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms, Sexual Dysfunction, Physiological

Prostatic Neoplasms

Advanced Prostate Adenocarcinoma

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Clinical Trials

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

CASPAR

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

CARLHA-2

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

ADOPT

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

URONCOR 06-24

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

DART

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

PRONOUNCE

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

HERO

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

A Study of Degarelix in Patients With Prostate Cancer

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Post-operative or Early Salvage XRT and ADT for High Risk PCa

ICELAND

Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy

Rising PSA

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

A Study of Leuprolide to Treat Prostate Cancer

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

Clinical Trial for Prostate Cancer